lexaria glp 1 Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain Lexaria Releases Phase 1b Study

According to FDA prescribing information, gallbladder-related adverse events occurred in clinical trials of semaglutide for weight management (Wegovy) at rates of 2.5% versus 1.0% with placebo, and for tirzepatide (Zepbound) at rates of 2.5% versus 1.0% with placebo

Learn how to lose weight without exercise through sustainable diet, sleep, and stress management

Constipation is common because slower transit means more water absorption from the stool

In fact, some early studies and patient reports indicate bloating and abdominal discomfort improve on GLP-1 therapy, likely due to the slowed, more gradual digestive process

While some individuals notice significant changes quickly, others may see gradual improvements

Further, GLP-1RA therapy was associated with reduced risks of stroke or TIA, MI, VTE, PE, all-cause mortality, hospitalization, and ED visits in participants with T2D